Radius faces delay on FDA review of abaloparatide

Shares in Radius Health (Nasdaq: RDUS) have fallen 5% on the news that the US Food and Drug Administration needs more time to review the company’s New Drug Application (NDA) for abaloparatide.

The FDA now expects to complete its review by June 30, 2017. The agency has not requested any additional information from the US-based biopharmaceutical company.

Abaloparatide is a novel synthetic peptide that Radius is developing as a treatment for women with postmenopausal osteoporosis who are at an increased risk for a fracture.